Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21653724 | 0.79 | EGFR (0.31) | LPLLIPGEGFR | |
| SCHEMBL25293069 | 0.76 | LPL (0.34) | LPLLIPG | |
| SCHEMBL30218086 | 0.75 | LPL (0.38) | LPLLIPGALDH1A1HSD17B10EGFR | |
| SCHEMBL15392736 | 0.75 | LPL (0.35) | LPLLIPG | |
| SCHEMBL29514317 | 0.75 | LPL (0.35) | LPLLIPG | |
| SCHEMBL660323 | 0.75 | LPL (0.35) | LPLLIPG | |
| SCHEMBL476865 | 0.75 | LPL (0.38) | LPLLIPGALDH1A1HSD17B10EGFR | |
| SCHEMBL25243940 | 0.74 | LPL (0.32) | LPLLIPGEGFR | |
| SCHEMBL32691558 | 0.74 | HSD17B10 (0.36) | LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL32691312 | 0.74 | LPL (0.32) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4339193-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-20230212161-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230212161-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2022237858-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-11-17 | — | — | WO | disclosed |
| CN-115340528-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2013173382-A1 | BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | LPL 4866/4885LIPG 4818/4885ALDH1A1 490/4885 |
| US-20230212161-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | AOX1, XDH, OCIAD1 | LPL 1157/4885LIPG 2155/4885ALDH1A1 293/4885 |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | LPL 3216/4885LIPG 2101/4885ALDH1A1 1826/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | LPL 2815/4885LIPG 3271/4885ALDH1A1 2586/4885 |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | STK4, STK3, STK11 | LPL 3216/4885LIPG 2101/4885ALDH1A1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.